Thursday 19 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterprise solutionsVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Pipeline & R&D

Optimi Health lines up larger psilocybin trial and MDMA pivotal study for 2027

The Canadian psychedelics developer wants to turn an open-label depression study into a blinded 200-patient trial, and says its PTSD Phase 3 already has regulatory clearance.

18 Nov 2026 · Optimi Health Corp. OPTH · Company news

Optimi Health Corp. is trying to move both of its lead psychedelic programmes into more rigorous clinical territory, a step that matters for any company hoping to turn early-stage promise into an asset that partners or investors can value. The Canadian developer set out its plans on 18 November 2026.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): Optimi Health Corp. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More Pipeline & R&DAll →